Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

Pruritus: early-phase trial registry

4 of 13 indexed Pruritus trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,315 of 28,707 conditions by registered trial count.

13 US clinical trials · 4 currently recruiting · #1,315 of 28,707 conditions by registered trial count

Pruritus: 13 US clinical trials tracked, 4 recruiting.

Pruritus is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Asana BioSciences, running 1 of these trials.

Enrollment posture brief

Registry condition pruritus

OPEN 4 | RECR 31% | LATE 2 | EARLY 7 | RANK #1315 | SPON 1

Nearest open-share peer: Acute Decompensated Heart Failure (31% recruiting · 13 trials)

ACL Injury61.5%Acute Biphenotypic Leukemia46.2%Pruritus (this)31%Accidental Falls30.8%Actinic Keratoses23.1%
Open-enrollment share among volume-matched conditions near Pruritus

Pruritus lists 4 open slots (31% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Pruritus on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Pruritus is recruiting below its size-band peers.

    4 of 13 indexed trials (30.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Pruritus trials is spread across many organizations.

    Asana BioSciences accounts for 1 of 13 trials (7.7%). 13 distinct sponsors appear on at least one study for this condition label.

  3. Most Pruritus trials plan to enrol fewer than 100 people.

    Median target enrolment is 53 among the 13 trials that report a genuine target (sentinel values excluded). 10 of those (76.9%) plan for fewer than 100 participants.

  4. Pruritus research is mostly interventional.

    13 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 25Phase 32

Open and recent trials

13 total, page 1 of 1

RECRUITING Phase 3 284 participants

Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)

Sanofi

NCT05263206

RECRUITING NA 60 participants

The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis

Nexgen Dermatologics

NCT06488742

RECRUITING NA 34 participants

VR-PMR for Post-Burn Symptoms

Johns Hopkins University

NCT07317271

RECRUITING NA 12 participants

Cervical Traction to Reduce Gabaergic Medication Use for Neuropathic Itch

Mayo Clinic

NCT06751056

COMPLETED Phase 2 547 participants

B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis

AOBiome

NCT04490109

COMPLETED Phase 2 144 participants

A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis

Formation Bio

NCT05870865

COMPLETED Phase 2 62 participants

Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

Escient Pharmaceuticals

NCT05525520

COMPLETED Phase 2 62 participants

Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis

Trevi Therapeutics

NCT02174419

COMPLETED NA 53 participants

Study Determining Safety and Efficacy of Avena Sativa (Oat) Skincare Products for Treating Skin Dryness and Itching in Cancer Patients

Johnson & Johnson Consumer Inc. (J&JCI)

NCT03796052

COMPLETED Phase 1 24 participants

Study to Evaluate ASN008 Topical Gel (TG)

Asana BioSciences

NCT03798561

COMPLETED Early Phase 1 20 participants

Defining N-Acetyl Cysteine as a Treatment for Inhibiting Prurogenic Stimuli

Wright State University

NCT05287724

COMPLETED Phase 3 15 participants

Gabapentin to Treat Itch in Patients With Liver Disease

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT00058890

COMPLETED Phase 2 14 participants

Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients

Jean Yuh Tang

NCT02654483

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 5
Phase 3 2

Named interventions

Most-linked intervention names on Pruritus records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
4 trials
Placebo TG Drug
1 trials
ASN008 TG Drug
1 trials
Placebo tablets BID Drug
1 trials
nalbuphine HCl ER tablets 180 mg BID Drug
1 trials
nalbuphine HCl ER tablets 90 mg BID Drug
1 trials
B244 Biological
1 trials
ASN008 Matching Vehicle Other
1 trials

US sites by state

Facility locations filed on Pruritus trials. A trial with sites in several states counts in each.

New York 6 trials
Ohio 5 trials
Florida 5 trials
California 5 trials
Arizona 4 trials
Texas 3 trials
Pennsylvania 3 trials
Louisiana 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Pruritus page

13 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pruritus condition card totals 13 registered trials; most-linked intervention Placebo; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.